BOLT - Company ID 0001641281
Bolt Biotherapeutics, Inc. trades as BOLT. In its fiscal 2025 annual report the company posted revenue of $7.70M, up 0.1% from the prior year and net income of -$33.38M. This page tracks Bolt Biotherapeutics, Inc. through 278 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 5 fiscal years Bolt Biotherapeutics, Inc.'s revenue grew from $231.00K to $7.70M, a compound annual growth rate of 101.6%. Net profit margin expanded from -26289.2% to -433.7% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Quarterly report | 10-Q | 2026-05-12 |
| Major company event | 8-K | 2026-05-12 |
| Annual report to shareholders | ARS | 2026-04-28 |
| Proxy materials | DEFA14A | 2026-04-28 |
| Proxy statement | DEF 14A | 2026-04-28 |
| Employee stock plan | S-8 | 2026-03-12 |
| Annual report | 10-K | 2026-03-12 |
| Major company event | 8-K | 2026-03-12 |
The largest companies sharing Bolt Biotherapeutics, Inc.'s SEC industry classification (pharmaceutical preparations).
Bolt Biotherapeutics, Inc. reported revenue of $7.70M for fiscal year 2025, an increase of 0.1% year over year.
In its latest fiscal year Bolt Biotherapeutics, Inc. reported a net loss of $33.38M.